BioSpace News Archive

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its participation in the Bioprocessing Summit Europe, taking place on March 19-21, 2024, in Barcelona, Spain.

ResMed, the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases, announced the results of its 2024 Global Sleep Survey in conjunction with World Sleep Day, shedding light on the critical sleep challenges faced by people around the world.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient, announced that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024.

Helius Medical Technologies, Inc. today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024, after the market closes.

BioXcel Therapeutics, Inc. today reported that the European Patent Office (EPO) granted the Company’s European Patent No. 3,562,486 (the “486 patent”) on March 13, 2024.

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy met its primary endpoint of overall survival for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer.

Mesa Laboratories, Inc. announced the release of its second annual Environmental, Social and Governance Program Brochure.

Soligenix, Inc. announced today its recent accomplishments and financial results for the year ended December 31, 2023.

Vapotherm, Inc., announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.

Navigate BioPharma Services, Inc. in Collaboration with Partners Validate Analytical Assay for Acute Myeloid Leukemia Measurable Residual Disease (AML-MRD) Assessment.